B4GALT7

Across TCGA pan-cancer cohorts, B4GALT7 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of B4GALT7’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where B4GALT7 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types B4GALT7 is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

HNSC, CCRCC, and LUAD are the cancer types where B4GALT7 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in B4GALT7 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+0.522	<.001	11	view →
CCRCC	All	III,IV	+0.448	<.001	11	view →
LUAD	Female	III,IV	+0.850	<.001	9	view →
LSCC	Female	All	+0.621	<.001	9	view →
COAD	All	II,III,IV	+0.352	<.001	8	view →
PDAC	Male	II,III,IV	−0.407	.010	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

B4GALT7–HNSC

Open the HNSC breakdown →